Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs - an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Harguindey, Salvador ^a   Arranz, Jose L ^a   Polo Orozco, Julian D ^a   Rauch, Cyril ^b   Fais, Stefano ^c   Cardone, Rosa A ^d   Reshkin, Stephan J ^d  

^a Instituto de Biología Clínica y Metabolismo IBCM   (Spain)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

Cancer etiopathogenesis; Cancer treatment; Cariporide in cancer; Multiple drug resistance; New therapeutic paradigm in cancer; NHE1 and cancer; pH and cancer; Proton transport inhibitors; Proton transporters

Indexed keywords

5 (N ETHYL N ISOPROPYL)AMILORIDE; 5 (N,N DIMETHYL)AMILORIDE; AMILORIDE; AMIODARONE; ANTINEOPLASTIC AGENT; BAFILOMYCIN A1; CAMPTOTHECIN; CARIPORIDE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; EDELFOSINE; ENIPORIDE; ESOMEPRAZOLE; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; MITOXANTRONE; NIGERICIN; PACLITAXEL; PHENOXAZINE DERIVATIVE; PLACEBO; SODIUM PROTON EXCHANGE PROTEIN 1; TAMOXIFEN; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE; ZONIPORIDE;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CELL; CANCER REGRESSION; CANCER RESISTANCE; CARCINOGENESIS; CARCINOGENICITY; CELL HYPOXIA; CELL PH; DRUG ACCUMULATION; DRUG DOSE COMPARISON; DRUG POTENTIATION; GLYCOLYSIS; HEART PROTECTION; HUMAN; INTRACELLULAR SIGNALING; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; POTASSIUM BLOOD LEVEL; PROTON TRANSPORT; REPERFUSION INJURY; REVIEW; SIDE EFFECT; SOLID TUMOR; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CATION TRANSPORT PROTEINS; GUANIDINES; HUMANS; HYDROGEN-ION CONCENTRATION; NEOPLASMS; SODIUM-HYDROGEN ANTIPORTER; SULFONES;

EID: 84887070095     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-282     Document Type: Review

References (200)

1. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 2005, 5:786-795. 10.1038/nrc1713, 16175178.
2. Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 2011, 11:671-677. 10.1038/nrc3110, 21833026.
3. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011, 10:767-777. 10.1038/nrd3554, 21921921.
4. Reshkin SJ, Cardone RA, Harguindey S. Na+-H+ exchanger, pH regulation and cancer. Recent Pat Anticancer Drug Discov 2013, 8:85-99.
5. Harguindey S, Arranz JL, Wahl ML, Orive G, Reshkin SJ. Proton transport inhibitors as potentially selective anticancer drugs. Anticancer Res 2009, 29:2127-2136.
6. Brisson L, Reshkin SJ, Gore J, Roger S. pH regulators in invadosomal functioning: proton delivery for matrix tasting. Eur J Cell Biol 2012, 91:847-860. 10.1016/j.ejcb.2012.04.004, 22673002.
7. Brisson L, Gillet L, Calaghan S, Besson P, Le Guennec J, Roger S, Gore J. NaV1. 5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H+ efflux in caveolae. Oncogene 2010, 30:2070-2076.
8. Rubin H, Fodge D. Interrelationships of sugar transport and the initiation of DNA synthesisin chick embryo cells. Control of Proliferation of Animal Cells 1974, 801-816. New York: Cold Spring Harbor Laboratory, Clarkson B, Baserga R.
9. Perona R, Serrano R. Increased pH and tumorigenicity of fibroblasts expressing a yeast proton pump. Nature 1988, 334:438-440. 10.1038/334438a0, 2900469.
10. Reshkin SJ, Bellizzi A, Caldeira S, Albarani V, Malanchi I, Poignee M, Alunni-Fabbroni M, Casavola V, Tommasino M. Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J 2000, 14:2185-2197. 10.1096/fj.00-0029com, 11053239.
11. Harguindey S, Pedraz JL, Garcia Canero R, Perez de Diego J, Cragoe EJ. Hydrogen ion-dependent oncogenesis and parallel new avenues to cancer prevention and treatment using a H(+)-mediated unifying approach: pH-related and pH-unrelated mechanisms. Crit Rev Oncog 1995, 6:1-33. 10.1615/CritRevOncog.v6.i1.20, 8573605.
12. Shimizu S, Eguchi Y, Kamiike W, Funahashi Y, Mignon A, Lacronique V, Matsuda H, Tsujimoto Y. Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. Proc Natl Acad Sci U S A 1998, 95:1455-1459. 10.1073/pnas.95.4.1455, 19042, 9465036.
13. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 2002, 9:12-16. 10.1038/nsb730, 11753428.
14. Aravena C, Beltran AR, Cornejo M, Torres V, Diaz ES, Guzman-Gutierrez E, Pardo F, Leiva A, Sobrevia L, Ramirez MA. Potential role of sodium-proton exchangers in the low concentration arsenic trioxide-increased intracellular pH and cell proliferation. PLoS One 2012, 7:e51451. 10.1371/journal.pone.0051451, 3516555, 23236503.
15. Grinstein S, Rotin D, Mason MJ. Na+/H+ exchange and growth factor-induced cytosolic pH changes. Role in cellular proliferation. Bioch Biophys Acta 1989, 988:73-97.
16. Wakabayashi S, Fafournoux P, Sardet C, Pouysségur J. The Na+/H+ antiporter cytoplasmic domain mediates growth factor signals and controls "H(+)-sensing" Proc Natl Acad Sci U S A 1992, 89:2424-2428. 10.1073/pnas.89.6.2424, 48670, 1372444.
17. Sun I, Crane F, Löw H. Bombesin stimulates transplasma-membrane electron transport by Swiss 3 T3 cells. Biochim Biophys Acta (BBA)-Mol Cell Res 1994, 1221:206-210.
18. Eagle H. Some effects of environmental pH on cellular metabolism and function. Control of Proliferation in Animal Cells Cold Spring Harbor Conference on Cell Proliferation 1974, New York: Cold Spring Harbor Laboratory.
19. Moolenaar WH. Effects of growth factors on intracellular pH regulation. Annu Rev Plant Physiol Plant Mol Biol 1986, 48:363-376.
20. Chiche J, Ilc K, Laferrière J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouysségur J. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009, 69:358-368. 10.1158/0008-5472.CAN-08-2470, 19118021.
21. Chiche J, Ricci JE, Pouysségur J. Tumor hypoxia and metabolism - towards novel anticancer approaches. Ann Endocrinol (Paris) 2013, 74(2):111-114. 10.1016/j.ando.2013.02.004, 23597945.
22. L'Allemain G, Paris S, Pouysségur J. Growth factor action and intracellular pH regulation in fibroblasts. Evidence for a major role of the Na+/H+ antiport. J Biol Chem 1984, 259:5809-5815.
23. Pouysségur J, Franchi A, L'Allemain G, Paris S. Cytoplasmic pH, a key determinant of growth factor-induced DNA synthesis in quiescent fibroblasts. FEBS Lett 1985, 190:115-119. 10.1016/0014-5793(85)80439-7, 4043390.
24. Pouysségur J, Chambard JC, Franchi A, Paris S, Van Obberghen-Schilling E. Growth factor activation of an amiloride-sensitive Na+/H+ exchange system in quiescent fibroblasts: coupling to ribosomal protein S6 phosphorylation. Proc Natl Acad Sci U S A 1982, 79:3935-3939. 10.1073/pnas.79.13.3935, 346550, 6287453.
25. Hagag N, Lacal JC, Graber M, Aaronson S, Viola MV. Microinjection of ras p21 induces a rapid rise in intracellular pH. Mol Cell Biol 1987, 7:1984-1988. 365306, 3037340.
26. Doppler W, Jaggi R, Groner B. Induction of v-mos and activated Ha-ras oncogene expression in quiescent NIH 3 T3 cells causes intracellular alkalinisation and cell-cycle progression. Gene 1987, 54:147-153. 10.1016/0378-1119(87)90357-X, 3038697.
27. Harguindey S, Orive G, Luis Pedraz J, Paradiso A, Reshkin SJ. The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin--one single nature. Biochim Biophys Acta Revs Cancer 2005, 1756:1-24.
28. Lopez-Lazaro M. A new view of carcinogenesis and an alternative approach to cancer therapy. Mol Med 2010, 16:144-153. 2802554, 20062820.
29. Harguindey S, Orive G, Cacabelos R, Hevia EM, De Otazu RD, Arranz JL, Anitua E. An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS). Neuropsychiatr Dis Treat 2008, 4:1073-1084. 2646641, 19337452.
30. Harguindey S, Reshkin SJ, Orive G, Arranz JL, Anitua E. Growth and trophic factors, pH and the Na+/H+ exchanger in Alzheimer's disease, other neurodegenerative diseases and cancer: new therapeutic possibilities and potential dangers. Curr Alzheimer Res 2007, 4:53-65. 10.2174/156720507779939841, 17316166.
31. Harguindey S, Cragoe EJ. The Na+/H+ antiporter in oncology in the light of the spontaneous regression of cancer and cell metabolism. Med Hypotheses 1992, 39:229-237. 10.1016/0306-9877(92)90114-R, 1335544.
32. Harguindey S. Integrating fields of cancer research through pivotal mechanisms and synthetic final pathways: a unifying and creative overview. Med Hypotheses 2002, 58:444-452. 10.1054/mehy.2001.1415, 12323109.
33. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 2006, 66:5216-5223. 10.1158/0008-5472.CAN-05-4193, 16707446.
34. Lauritzen G, Stock CM, Lemaire J, Lund SF, Jensen MF, Damsgaard B, Petersen KS, Wiwel M, Ronnov-Jessen L, Schwab A, Pedersen SF. The Na+/H+ exchanger NHE1, but not the Na+, HCO3(-) cotransporter NBCn1, regulates motility of MCF7 breast cancer cells expressing constitutively active ErbB2. Cancer Lett 2012, 317:172-183. 10.1016/j.canlet.2011.11.023, 22120673.
35. Bhujwalla ZM, Artemov D, Ballesteros P, Cerdan S, Gillies RJ, Solaiyappan M. Combined vascular and extracellular pH imaging of solid tumors. NMR Biomed 2002, 15:114-119. 10.1002/nbm.743, 11870907.
36. Ludwig F, Schwab A, Stock C. The Na (+)/H(+)-exchanger (NHE1) generates pH nanodomains at focal adhesions. J Cell Physiol 2012, 228(6):1351-1358.
37. Amith SR, Fliegel L. Regulation of the Na+/H+ Exchanger (NHE1) in Breast Cancer Metastasis. Cancer Res 2013, 73:1259-1264. 10.1158/0008-5472.CAN-12-4031, 23393197.
38. Rich IN, Worthington-White D, Garden OA, Musk P. Apoptosis of leukemic cells accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. Blood 2000, 95:1427-1434.
39. Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2011, 2:49. 3161244, 21904528.
40. Parks S, Chiche J, Pouysségur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Cancer Revs 2013, 13:611-623.
41. Kaminskas E. The pH-dependence of sugar-transport and glycolysis in cultured Ehrlich ascites-tumour cells. Biochem J 1978, 174:453-459. 1185934, 30454.
42. Relman AS. Metabolic consequences of acid-base disorders. Kidney Int 1972, 1:347-359. 10.1038/ki.1972.46, 4275852.
43. Wilhelm G, Schulz J, Hofmann E. pH-dependence of aerobic glycolysis in ehrlich ascites tumour cells. FEBS Lett 1971, 17:158. 10.1016/0014-5793(71)80587-2, 11946020.
44. Nagata H, Che XF, Miyazawa K, Tomoda A, Konishi M, Ubukata H, Tabuchi T. Rapid decrease of intracellular pH associated with inhibition of Na+/H+ exchanger precedes apoptotic events in the MNK45 and MNK74 gastric cancer cell lines treated with 2-aminophenoxazine-3-one. Oncol Rep 2011, 25:341-346.
45. Che X-F, Zheng C-L, Akiyama S-I, Tomoda A. 2-Aminophenoxazine-3-one and 2-amino-4,4α-dihydro-4α,7-dimethyl-3H-phenoxazine-3-one cause cellular apoptosis by reducing higher intracellular pH in cancer cells. Proc Japan Acad, Series B Phys Biol Sci 2011, 87:199-213.
46. Harguindey S, Henderson ES, Naeher C. Effects of systemic acidification of mice with Sarcoma 180. Cancer Res 1979, 39:4364-4371.
47. Trivedi B, Danforth WH. Effect of pH on the kinetics of frog muscle phosphofructokinase. J Biol Chem 1966, 241:4110-4114.
48. Gillies RJ. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng 2005, 7:287-326. 10.1146/annurev.bioeng.7.060804.100411, 16004573.
49. Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjaer-Larsen JH, Zandt R, Jensen PR, Karlsson M, Golman K, Lerche MH, Brindle KM. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 2008, 453:940-943. 10.1038/nature07017, 18509335.
50. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 1996, 56:1194-1198.
51. Lutz N, Le Fur Y, Chiche J, Pouysségur J, Cozzone P. Quantitative in-vivo characterization of intracellular and extracellular pH profiles in heterogeneous tumors: a novel method enabling multiparametric pH analysis. Cancer Res 2013, 76:4616-4628.
52. Goldblatt H, Friedman L, Cechner R. On the malignant transformation of cells during prolonged culture under hypoxic conditions in vitro. Biochem Med 1973, 7:241. 10.1016/0006-2944(73)90079-3, 4704459.
53. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314. 10.1126/science.123.3191.309, 13298683.
54. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927, 8:519-530. 10.1085/jgp.8.6.519, 2140820, 19872213.
55. Goldfeder A. Theoretical basis for the acidotic treatment of neoplasia. Am J Surg 1933, 19:307-312.
56. Burk D. A Colloquial Consideration of the Pasteur and Neo-Pasteur Effects. Cold Spring Harb Symp Quant Biol 1939, 7:420-459.
57. Cori CF, Cori GT. The carbohydrate metabolism of tumors. I. The free sugar, lactic acid, and glycogen content of malignant tumors. J Biol Chem 1925, 64:11-22.
58. Eagle H. The effect of environmental pH on the growth of normal and malignant cells. J Cell Physiol 1973, 82:1-8. 10.1002/jcp.1040820102, 4354070.
59. Calderon-Montano JSJ, Robles A, Lopez Lazaro M. Role of the Intracellular pH in the Metabolic Switch between Oxidative Phosphorylation and Aerobic Glycolysis - Relevance to Cancer. WebmedCentral CANCER 2011, 2:3. WMC001716.
60. Warburg O. The Prime Cause and Prevention of Cancer 1967, Würzburg, Germany: Konrad Triltsch, The Nobel Lecture, June 1966.
61. Warburg O. The Metabolism of Tumors 1930, London: Constable.
62. Weinhouse S. On respiratory impairment in cancer cells. Science 1956, 124:267-269. 10.1126/science.124.3215.267, 13351638.
63. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4:891-899. 10.1038/nrc1478, 15516961.
64. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010, 10:267-277. 10.1038/nrc2817, 20300106.
65. Ristow M. Oxidative metabolism in cancer growth. Curr Opin Clin Nutr Metab Care 2006, 9:339-345. 10.1097/01.mco.0000232892.43921.98, 16778561.
66. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E. Energy metabolism in tumor cells. FEBS J 2007, 274:1393-1418. 10.1111/j.1742-4658.2007.05686.x, 17302740.
67. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011, 11:325-337. 10.1038/nrc3038, 21508971.
68. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707. 10.1016/j.cell.2008.08.021, 18775299.
69. Burk D, Woods M, Hunter J. On the significance of glucolysis for cancer growth, with special reference to Morris rat hepatomas. J Nat Cancer Inst 1967, 38:839-863.
70. Kritikou E. Metabolism: Warburg effect revisited. Nature Rev Cancer 2008, 8:247-247.
71. Kroemer G, Pouysségur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482. 10.1016/j.ccr.2008.05.005, 18538731.
72. Rietman EA, Friesen DE, Hahnfeldt P, Gatenby R, Hlatky L, Tuszynski JA. An integrated multidisciplinary model describing initiation of cancer and the Warburg hypothesis. Theoret Biol Med Model 2013, 10:39. doi:10.1186/1742-4682-1110-1139.
73. Bailey KM, Wojtkowiak JW, Hashim AI, Gillies RJ. Targeting the metabolic microenvironment of tumors. Adv Pharmacol 2012, 65:63-107. 3796340, 22959024.
74. Parks S, Chiche J, Pouysségur J. pH control mechanisms of tumor survival and growth. J Cell Physiol 2011, 226:299-308. 10.1002/jcp.22400, 20857482.
75. Pedersen SF, Stock C. Ion Channels and Transporters in Cancer: Pathophysiology, Regulation, and Clinical Potential. Cancer Res 2013, 73:1658-1661. 10.1158/0008-5472.CAN-12-4188, 23302229.
76. Izumi H, Torigoe T, Ishiguchi H, Uramoto H, Yoshida Y, Tanabe M, Ise T, Murakami T, Yoshida T, Nomoto M, Kohno K. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Revs 2003, 29:541-549.
77. Moriyama Y, Nelson N. Inhibition of vacuolar H+-ATPases by fusidic acid and suramin. FEBS letters 1988, 234:383. 10.1016/0014-5793(88)80121-2, 2899033.
78. Donowitz M, Tse CM, Fuster D. SLC9/NHE gene family, a plasma membrane and organellar family of Na+/H+ exchangers. Mol Aspects Med 2013, 34:236-251. 10.1016/j.mam.2012.05.001, 3724465, 23506868.
79. Boedtkjer E, Bunch L, Pedersen SF. Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: similarities, differences, and implications for cancer therapy. Curr Pharm Des 2012, 18:1345-1371. 10.2174/138161212799504830, 22360557.
80. Stock C, Cardone RA, Busco G, Krahling H, Schwab A, Reshkin SJ. Protons extruded by NHE1: digestive or glue?. Eur J Cell Biol 2008, 87:591-599. 10.1016/j.ejcb.2008.01.007, 18328592.
81. Stock C, Ludwig FT, Schwab A. Is the multifunctional Na(+)/H(+) exchanger isoform 1 a potential therapeutic target in cancer?. Curr Med Chem 2012, 19:647-660. 10.2174/092986712798992101, 22204338.
82. Rauch C, Blanchard A, Wood E, Dillon E, Whal M, Harguindey S. Multiple Drug Resistance. Cell Membranes, Cytosolic pH and Drug Transport in Cancer and MDR: Physics, Biochemistry and Molecular Biology 2009, New York: Nova, Meszaros A, Balogh G.
83. Daniel C, Bell C, Burton C, Harguindey S, Reshkin SJ, Rauch C. The role of proton dynamics in the development and maintenance of multidrug resistance in cancer. Biochim Biophys Acta 1832, 2013:606-617.
84. McLean LA, Roscoe J, Jørgensen NK, Gorin FA, Cala PM. Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed astrocytes. Am J Physiol-Cell Physiol 2000, 278:C676-C688.
85. Xu K, Mao X, Mehta M, Cui J, Zhang C, Mao F, Xu Y. Elucidation of How Cancer Cells Avoid Acidosis through Comparative Transcriptomic Data Analysis. PloS one 2013, 8:e71177. 10.1371/journal.pone.0071177, 3743895, 23967163.
86. Harguindey S. Amiloride and its Analogs: Unique Cation Transport Inhibitors. Use of Na+/H+ Antiporter Inhibitors as a Novel Approach to Cancer Treatment 1992, 317-334. New York: VCH Publishers, Cragoe EJJr, ThR K, Simchowitz L.
87. Loo SY, Chang MK, Chua CS, Kumar AP, Pervaiz S, Clement MV. NHE-1: a promising target for novel anti-cancer therapeutics. Curr Pharm Des 2012, 18:1372-1382. 10.2174/138161212799504885, 22360552.
88. Huber V, De Milito A, Harguindey S, Reshkin SJ, Wahl ML, Rauch C, Chiesi A, Pouysségur J, Gatenby RA, Rivoltini L, Fais S. Proton dynamics in cancer. J Transl Med 2010, 8:57. 10.1186/1479-5876-8-57, 2905351, 20550689.
89. Provost JJ, Wallert MA. Inside out: targeting NHE1 as an intracellular and extracellular regulator of cancer progression. Chem Biol & Drug Design 2013, 81:85-101.
90. Fliegel L, Fröhlich O. The Na+/H+ exchanger: an update on structure, regulation and cardiac physiology. Biochem J 1993, 296:273. 1137689, 8257412.
91. Jankun JS-JE. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. Cancer Bioch Biophys 1999, 17:109-123.
92. He B, Deng C, Zhang M, Zou D, Xu M. Reduction of intracellular pH inhibits the expression of VEGF in K562 cells after targeted inhibition of the Na+/H+ exchanger. Leuk Res 2007, 31:507-514. 10.1016/j.leukres.2006.06.015, 16884771.
93. Provost JJ, Rastedt D, Canine J, Ngyuen T, Haak A, Kutz C, Berthelsen N, Slusser A, Anderson K, Dorsam G. Urokinase plasminogen activator receptor induced non-small cell lung cancer invasion and metastasis requires NHE1 transporter expression and transport activity. Cell Oncol 2012, 35:95-110.
94. Kim T-D, Song K-S, Li G, Choi H, Park H-D, Lim K, Hwang B-D, Yoon W-H. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 2006, 6:211. doi:210.1186/1471-2407-1186-1211, 10.1186/1471-2407-6-211, 1563482, 16916471.
95. Kellen J, Mirakian A, Kolin A. Antimetastatic effect of amiloride in an animal tumour model. Anticancer Res 1988, 8:1373-1376.
96. Harguindey S, Orive G, Pedraz J, Bello G, Arranz J, Samaniego J. Apparent cure of a cases of metastatic ovarian carcinoma alter chronic treatment with Na+-H+ antiporter inhibitors. Oncologia Madrid 2002, 25:472-476.
97. Matthews H, Ranson M, Kelso M. Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty?. Intern J Cancer 2011, 129:2051.2061.
98. Alliegro MC, Alliegro MA, Cragoe EJ, Glaser BM. Amiloride inhibition of angiogenesis in vitro. J Exp Zool 1993, 267:245-252. 10.1002/jez.1402670302, 7693860.
99. Junior J. Metastatic neuroendocrine carcinoma of the pancreas - case report and literature review. Rev Brasil Oncol 2010, 7(21):24-30.
100. Bellizzi A, Mangia A, Malfettone A, Cardone RA, Simone G, Reshkin SJ, Paradiso A. Na+/H+ exchanger regulatory factor 1 expression levels in blood and tissue predict breast tumour clinical behaviour. Histopathology 2011, 58:1086-1095. 10.1111/j.1365-2559.2011.03844.x, 21707710.
101. Harguindey SMF, Gonzalez Molinillo JM, Chinchilla D, Reshkin SJ, Tomoda A. Further Along a Clinical Protocol Using a Cocktail of PTIs in Human Cancer. ISPDC Abstract Book, 2nd ISPD Meeting, Nice, France, 18-19, 2011 2011
102. Vairo G, Cocks B, Cragoe E, Hamilton J. Selective suppression of growth factor-induced cell cycle gene expression by Na+/H+ antiport inhibitors. J Biol Chem 1992, 267:19043-19046.
103. Hosogi SMH, Nakajima K, Ashihara E, Niisato N, Kusuzaki K, Marunaka Y. An inhibitor of Na(+)/H(+) exchanger (NHE), ethyl-isopropyl amiloride (EIPA), diminishes proliferation of MKN28 human gastric cancer cells by decreasing the cytosolic Cl(-) concentration via DIDS-sensitive pathways. Cell Physiol Biochem 2012, 30:1241-1253. 10.1159/000343315, 23075671.
104. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 2013, 497:633-637. 10.1038/nature12138, 3810415, 23665962.
105. Masereel B, Pochet L, Laeckmann D. An overview of inhibitors of Na+/H+ exchanger. Europ J Med Chemis 2003, 38:547-554.
106. Harguindey S, Pedraz JL, Canero RG, Katin M. Edelfosine, apoptosis, MDR and Na+/H+ exchanger: induction mechanisms and treatment implications. Apoptosis 2000, 5:87-89. 10.1023/A:1009645927931, 11227496.
107. Orive G, Reshkin SJ, Harguindey S, Pedraz JL. Hydrogen ion dynamics and the Na+/H+ exchanger in cancer angiogenesis and antiangiogenesis. Br J Cancer 2003, 89:1395-1399. 10.1038/sj.bjc.6601286, 2394349, 14562004.
108. Mo X, Chen Q, Li X, Zheng M, Ke D, Deng W, Li G, Jiang J, Wu Z, Wang L. Suppression of NHE1 by small interfering RNA inhibits HIF-1α-induced angiogenesis in vitro via modulation of calpain activity. Microvasc Res 2011, 81:160. 10.1016/j.mvr.2010.12.004, 21185840.
109. Lucien F, Brochu-Gaudreau K, Arsenault D, Harper K, Dubois CM. Hypoxia-induced invadopodia formation involves activation of NHE-1 by the p90 ribosomal S6 kinase (p90RSK). PloS one 2011, 6:e28851. 10.1371/journal.pone.0028851, 3246449, 22216126.
110. Jin W, Li Q, Wang J, Chang G, Lin Y, Li H, Wang L, Gao W, Pang T. Na+/H+ exchanger 1 inhibition contributes to K562 leukaemic cell differentiation. Cell Biol Int 2012, 36:739-745. 10.1042/CBI20100919, 22494070.
111. Busco G, Cardone RA, Greco MR, Bellizzi A, Colella M, Antelmi E, Mancini MT, Dell'Aquila ME, Casavola V, Paradiso A, Reshkin SJ. NHE1 promotes invadopodial ECM proteolysis through acidification of the peri-invadopodial space. FASEB J 2010, 24:3903-3915. 10.1096/fj.09-149518, 20547664.
112. Di Sario A, Bendia E, Omenetti A, De Minicis S, Marzioni M, Kleemann HW, Candelaresi C, Saccomanno S, Alpini G, Benedetti A. Selective inhibition of ion transport mechanisms regulating intracellular pH reduces proliferation and induces apoptosis in cholangiocarcinoma cells. Dig Liver Dis 2007, 39:60-69. 10.1016/j.dld.2006.07.013, 16982221.
113. Rupprecht H-J, Vom Dahl J, Terres W, Seyfarth KM, Richardt G, Schultheiβ H-P, Buerke M, Sheehan FH, Drexler H. Cardioprotective effects of the Na+/H+ exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation 2000, 101:2902-2908. 10.1161/01.CIR.101.25.2902, 10869261.
114. Boyce SW, Bartels C, Bolli R, Chaitman B, Chen JC, Chi E, Jessel A, Kereiakes D, Knight J, Thulin L. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. J Thor Cardiovasc Surg 2003, 126:420-427.
115. Chaitman BR. A Review of the GUARDIAN Trial Results: Clinical Implications and the Significance of Elevated Perioperative CK-MB on 6-Month Survival. J Cardiac Surg 2003, 18:13-20.
116. Mentzer RM, Bartels C, Bolli R, Boyce S, Buckberg GD, Chaitman B, Haverich A, Knight J, Menasché P, Myers ML. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thor Surg 2008, 85:1261-1270.
117. Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, Linssen G, Tebbe U, Schroder R, Tiemann R, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 2001, 38:1644-1650. 10.1016/S0735-1097(01)01608-4, 11704395.
118. Theroux P, Chaitman B, Danchin N, Erhardt L, Meinertz T, Schroeder J, Tognoni G, White H, Willerson J, Jessel A. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations: main results of the GUARDIAN trial. Circulation 2000, 102:3032-3038. 10.1161/01.CIR.102.25.3032, 11120691.
119. Avkiran M, Cook A, Cuello F. Targeting Na+/H+ exchanger regulation for cardiac protection: a RSKy approach?. Current Opin Pharmacol 2008, 8:133.
120. Linz WLHWA, Albus U. Long-term treatment with the NHE1-inhibitor cariporide extends the normal lifespan of Wistar Kyoto rats. Eur Heart J 2001, 22:148.
121. Reshkin SJ, Bellizzi A, Cardone RA, Tommasino M, Casavola V, Paradiso A. Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res 2003, 9:2366-2373.
122. Baartscheer A, Schumacher CA, Van Borren MM, Belterman CN, Coronel R, Opthof T, Fiolet JW. Chronic inhibition of Na+/H+-exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure. Cardiovasc Res 2005, 65:83-92. 10.1016/j.cardiores.2004.09.024, 15621036.
123. Kilic A, Velic A, De Windt LJ, Fabritz L, Voss M, Mitko D, Zwiener M, Baba HA, Van Eickels M, Schlatter E. Enhanced activity of the myocardial Na+/H+ exchanger NHE-1 contributes to cardiac remodeling in atrial natriuretic peptide receptor-deficient mice. Circulation 2005, 112:2307-2317. 10.1161/CIRCULATIONAHA.105.542209, 16216978.
124. Humphreys RA, Haist JV, Chakrabarti S, Feng Q, Arnold JMO, Karmazyn M. Orally administered NHE1 inhibitor cariporide reduces acute responses to coronary occlusion and reperfusion. Amer J Physiol-Heart Circulat Physiol 1999, 276:H749-H757.
125. Dhein S, Salameh A. Na+/H+-Exchange Inhibition by Cariporide (Hoe 642): A New Principle in Cardiovascular Medicine. Cardiovasc Drug Revs 1999, 17:134-146.
126. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia and cancer. J Mol Med Berl 2007, 85:1301-1307. 10.1007/s00109-007-0281-3, 18026916.
127. Brahimi-Horn C, Pouysségur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 2006, 93:E73-80.
128. Lv C, Yang X, Yu B, Ma Q, Liu B, Liu Y. Blocking the Na+/H+ exchanger 1 with cariporide (HOE642) reduces the hypoxia-induced invasion of human tongue squamous cell carcinoma. Intern J Oral Maxillofac Surg 2012, 41:1206-1210.
129. Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443. 10.1038/nature04871, 16724055.
130. Gao W, Chang G, Wang J, Jin W, Wang L, Lin Y, Li H, Ma L, Li Q, Pang T. Inhibition of K562 leukemia angiogenesis and growth by selective Na+/H+ exchanger inhibitor cariporide through down-regulation of pro-angiogenesis factor VEGF. Leuk Res 2011, 35:1506-1511. 10.1016/j.leukres.2011.07.001, 21784521.
131. Shi Q, Le X, Wang B, Abbruzzese JL, Xiong Q, He Y, Xie K. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 2001, 20:3751. 10.1038/sj.onc.1204500, 11439338.
132. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001, 61:6020-6024.
133. Xu LFD, Jain RK. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem 2002, 277(13):11368-11374. 10.1074/jbc.M108347200, 11741977.
134. Yang XWD, Dong W, Song Z, Dou K. Inhibition of Na(+)/H(+) exchanger 1 by 5-(N-ethyl-N-isopropyl) amiloride reduces hypoxia-induced hepatocellular carcinoma invasion and motility. Cancer Lett 2010, 2952:198-204.
135. Avery RL, Connor TB, Farazdaghi M. Systemic Amiloride Inhibits Experimentally Induced Neovascularization. Archiv Ophtalmol 1990, 108:1474-1476.
136. Aihara K, Hisa H, Sato T, Yoneyama F, Sasamori J, Yamaguchi F, Yoneyama S, Mizuno Y, Takahashi A, Nagai A. Cardioprotective effect of TY-12533, a novel Na(+)/H(+) exchange inhibitor, on ischemia/reperfusion injury. Europ J Pharmacol 2000, 404:221-229.
137. Guzman-Perez A, Wester RT, Allen MC, Brown JA, Buchholz AR, Cook ER, Day WW, Hamanaka ES, Kennedy SP, Knight DR. Discovery of zoniporide: A potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility. Bioorg Medicin Chem Letts 2001, 11:803-807.
138. Fukumoto S, Imamiya E, Kusumoto K, Fujiwara S, Watanabe T, Shiraishi M. Novel, Non-Acylguanidine-Type Na+/H+ Exchanger Inhibitors: Synthesis and Pharmacology of 5-Tetrahydroquinolinylidene Aminoguanidine Derivatives. J Med Chem 2002, 45:3009-3021. 10.1021/jm0104567, 12086486.
139. Martínez-Zaguilán R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, Smith D, Dalton WS, Gillies RJ. pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol 1999, 57:1037-1046. 10.1016/S0006-2952(99)00022-2, 10796074.
140. Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Ca Inst 2004, 96:1702-1713.
141. Roepe PD, Wei LY, Cruz J, Carlson D. Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein. Biochemistry 1993, 32:11042-11056. 10.1021/bi00092a014, 8105888.
142. Miraglia E, Viarisio D, Riganti C, Costamagna C, Ghigo D, Bosia A. Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin. Int J Cancer 2005, 115:924-929. 10.1002/ijc.20959, 15729714.
143. Milosavljevic N, Blanchard A, Wahl ML, Harguindey S, Poet M, Counillon L, Rauch C. Teaching new dogs old tricks: membrane biophysical properties in drug delivery and resistance. Recent Pat Anticancer Drug Discov 2011, 6:334-346. 10.2174/157489211796957829, 21756245.
144. Harguindey S, Gillis M. Evolution and cancer: possible relationships to changes in environmental hydrogen ion concentration. J Theor Biol 1980, 86:487-492. 10.1016/0022-5193(80)90347-1, 7218821.
145. Lee H-O, Silva AS, Li Y-S, Slifker M, Gatenby RA, Cheng JD. Evolution of tumor invasiveness: the adaptive tumor microenvironment landscape model. Cancer Res 2011, 71:6327-6337. 10.1158/0008-5472.CAN-11-0304, 3197231, 21859828.
146. Alfarouk KO, Ibrahim ME, Gatenby RA, Brown JS. Riparian ecosystems in human cancers. Evolut Applications 2013, 6:46-53.
147. De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol 2005, 1:779-786. 10.2217/14796694.1.6.779, 16556057.
148. Li J, Eastman A. Apoptosis in an Interleukin-2-dependent Cytotoxic T Lymphocyte Cell Line Is Associated with Intracellular Acidification. Role of the Na+/H+ antiport. J Biol Chem 1995, 270:3203-3211. 10.1074/jbc.270.7.3203, 7852405.
149. Pérez-Sala D, Collado-Escobar D, Mollinedo F. Intracellular alkalinization suppresses lovastatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease. J Biol Chem 1995, 270:6235-6242. 10.1074/jbc.270.11.6235, 7890761.
150. Reynolds JE, Li J, Craig RW, Eastman A. BCL-2 and MCL-1 expression in Chinese hamster ovary cells inhibits intracellular acidification and apoptosis induced by staurosporine. Exp Cell Res 1996, 225:430-436. 10.1006/excr.1996.0194, 8660932.
151. Keizer HG, Joenje H. Increased cytosolic pH in multidrug-resistant human lung tumor cells: effect of verapamil. J Nat Cancer Inst 1989, 81:706-709. 10.1093/jnci/81.9.706, 2565404.
152. Lagadic-Gossmann D, Huc L, Lecureur V. Alterations of intracellular pH homeostasis in apoptosis: origins and roles. Cell Death Differ 2004, 11:953-961. 10.1038/sj.cdd.4401466, 15195071.
153. De Milito AFS. Proton pump inhibitors may reduce tumour resistance. Expert Opin Pharmacother 2005, 6:1049-1054. 10.1517/14656566.6.7.1049, 15957961.
154. Fais S. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Int Med 2010, 267:515-525.
155. Lindner D, Raghavan D. Intra-tumoural extra-cellular pH: a useful parameter of response to chemotherapy in syngeneic tumour lines. Br J Cancer 2009, 100:1287-1291. 10.1038/sj.bjc.6605022, 2676543, 19367285.
156. Torigoe T, Izumi H, Ise T, Murakami T, Uramoto H, Ishiguchi H, Yoshida Y, Tanabe M, Nomoto M, Kohno K. Vacuolar H+-ATPase: functional mechanisms and potential as a target for cancer chemotherapy. Anticancer Drugs 2002, 13:237-243. 10.1097/00001813-200203000-00005, 11984067.
157. Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, Izumi H, Nakamura T, Matsuo K, Yamada Y. Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance. Intern J Cancer 2001, 93:869-874.
158. Paris S, Pouysségur J. Growth factors activate the Na+/H+ antiporter in quiescent fibroblasts by increasing its affinity for intracellular H+. J Biol Chem 1984, 259:10989-10994.
159. Thiebaut F, Currier S, Whitaker J, Haugland R, Gottesman M, Pastan I, Willingham M. Activity of the multidrug transporter results in alkalinization of the cytosol: measurement of cytosolic pH by microinjection of a pH-sensitive dye. J Histochem Cytochemist 1990, 38:685.
160. Boscoboinik D, Gupta R, Epand R. Investigation of the relationship between altered intracellular pH and multidrug resistance in mammalian cells. Br J Cancer 1990, 61:568. 10.1038/bjc.1990.127, 1971365, 2158805.
161. Rauch C, Pluen A. Multi drug resistance-dependent "vacuum cleaner" functionality potentially driven by the interactions between endocytosis, drug size and Pgp-like transporters surface density. Europ Biophs J 2007, 36:121-131.
162. Thews O, Gassnery B, Kelleher DK, Schwerdty G, Gekley M. Impact of Extracellular Acidity on the Activity of P-glycoprotein and the Cytotoxicity of Chemotherapeutic Drugs. Neoplasia 2006, 8:143-152. 10.1593/neo.05697, 1578510, 16611407.
163. Rauch C, BA W, Eleanor D, Miriam L, Wahl, Harguindey S. Cell Membranes, Cytosolic pH and Drug Transport in Cancer and MDR: Physics, Biochemistry and Molecular Biology. Multiple Drug Resistance 2009, 1-24. Hauppauge NY: Nova Science Publishers, Inc, Agoston M, Gusztav B.
164. Weichert A, Faber S, Jansen H, Scholz W, Lang H. Synthesis of the highly selective Na+/H+ exchange inhibitors cariporide mesilate and (3-methanesulfonyl-4-piperidino-benzoyl) guanidine methanesulfonate. Arzneimittelforschung 1997, 47:1204.
165. Parks SK, Mazure NM, Counillon L, Pouysségur J. Hypoxia promotes tumor cell survival in acidic conditions by preserving ATP levels. J Cell Physiol 2013, 28(9):1854-1862.
166. L'Allemain G, Franchi A, Cragoe E, Pouysségur J. Blockade of the Na+/H+ antiport abolishes growth factor-induced DNA synthesis in fibroblasts. Structure-activity relationships in the amiloride series. J Biol Chem 1984, 259:4313-4319.
167. Fang B, Wang D, Huang M, Yu G, Li H. Hypothesis on the Relationship Between the Change in Intracellular pH and Incidence of Sporadic Alzheimer's Disease or Vascular Dementia. Internat J Neurosci 2010, 120:591-595.
168. Vincent AM, TenBroeke M, Maiese K. Neuronal intracellular pH directly mediates nitric oxide-induced programmed cell death. J Neurobiol 1999, 40:171-184. 10.1002/(SICI)1097-4695(199908)40:2<171::AID-NEU4>3.0.CO;2-F, 10413448.
169. Rauch C. Toward a mechanical control of drug delivery. On the relationship between Lipinski's 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data. Eur Biophys J 2009, 38:829-846. 10.1007/s00249-009-0429-x, 19296096.
170. Raghunand N, He X, Van Sluis R, Mahoney B, Baggett B, Taylor C, Paine-Murrieta G, Roe D, Bhujwalla Z, Gillies R. Enhancement of chemotherapy by manipulation of tumour pH. Brit J Cancer 1999, 80:1005. 10.1038/sj.bjc.6690455, 2363059, 10362108.
171. Iessi E, Marino ML, Lozupone F, Fais S, De Milito A. Tumor acidity and malignancy: novel aspects in the design of anti-tumor therapy. Cancer Ther 2008, 6:55-66.
172. Altan N, Chen Y, Schindler M, Simon SM. Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 1998, 187:1583-1598. 10.1084/jem.187.10.1583, 2212293, 9584137.
173. Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Therap 2000, 85:217-229.
174. Raghunand N, Mahoney BP, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics: II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol 2003, 66:1219-1229. 10.1016/S0006-2952(03)00468-4, 14505801.
175. Raghunand N, Marti{dotless}́nez-Zaguilthomamper R, Wright SH, Gillies RJ. pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol 1999, 57:1047-1058. 10.1016/S0006-2952(99)00021-0, 10796075.
176. Rauch C. On the relationship between drug's size, cell membrane mechanical properties and high levels of multi drug resistance: a comparison to published data. Europ Biophys J 2009, 38:537-546.
177. Bell C, Hill C, Burton C, Blanchard A, Shephard F, Rauch C. Importance of the Difference in Surface Pressures of the Cell Membrane in Doxorubicin Resistant Cells That do not Express Pgp and ABCG2. Cell Biochem Biophys 2013, 1:14.
178. De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Ca Res 2007, 67:5408-5417.
179. De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Internat J Cancer 2010, 127:207-219.
180. Ruiz-Meana M, Garcia-Dorado D, Pina P, Inserte J, Agulló L, Soler-Soler J. Cariporide preserves mitochondrial proton gradient and delays ATP depletion in cardiomyocytes during ischemic conditions. Am J Physiol-Heart Circulat Physiol 2003, 285:H999-H1006.
181. Marches R, Vitetta ES, Uhr JW. A role for intracellular pH in membrane IgM-mediated cell death of human B lymphomas. PNAS U S A 2001, 98:3434-3439.
182. Severin T, Müller B, Giese G, Uhl B, Wolf B, Hauschildt S, Kreutz W. pH-dependent LAK cell cytotoxicity. Tumor Biol 2009, 15:304-310.
183. Lardner A. The effects of extracellular pH on immune function. J Leuk Biol 2001, 69:522-530.
184. Loeffler D, Juneau P, Heppner G. Natural killer-cell activity under conditions reflective of tumor micro-environment. Intern J Cancer 1991, 48:895.
185. Fischer B, Müller B, Fischer K-G, Baur N, Kreutz W. Acidic pH inhibits non-MHC-restricted killer cell functions. Clinic Immunol 2000, 96:252-263.
186. Fischer B, Müller B, Fisch P, Kreutz W. An acidic microenvironment inhibits antitumoral non-major histocompatibility complex-restricted cytotoxicity: implications for cancer immunotherapy. J Immunother 2000, 23:196-207. 10.1097/00002371-200003000-00004, 10746546.
187. Haveman J. The pH of the cytoplasm as an important factor in the survival of in vitro cultured malignant cells after hyperthermia. Effects of carbonylcyanide 3-chlorophenylhydrazone. Eur J Cancer 1979, 15:1281-1288. 10.1016/0014-2964(79)90255-X, 42545.
188. Haveman J. The influence of pH on the survival after X-irradiation of cultured malignant cells. Effects of carbonylcyanide-3-chlorophenylhydrazone. Int J Rad Biol 1980, 37(2):201-205.
189. Choi SYCC, Gout PW, Wang Y. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?. J Pathol 2013, 230(4):350-355. 10.1002/path.4218, 3757307, 23729358.
190. Shi Y, Kim D, Caldwell M, Sun D. The role of Na(+)/h(+) exchanger isoform 1 in inflammatory responses: maintaining H(+) homeostasis of immune cells. Adv Exp Med Biol 2013, 961:411-418. 10.1007/978-1-4614-4756-6_35, 23224899.
191. Arig I-H, Wojtkowiak JW, Cohelo Ribeiro ML, Estrella V, Bailey KM, Cornnell HH, Gatenby RA, Gillies RJ. Free Base Lysine Increases Survival and Reduces Metastasis in Prostate Cancer Model. J Cancer Sci Ther 2011, Suppl 1(4):1-7. http://dx.doi.org/10.4172/1948-5956.S1-004.
192. Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, Hashim AI, Morse DL, Raghunand N, Gatenby RA, Gillies RJ. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res 2009, 69:2260-2268. 10.1158/0008-5472.CAN-07-5575, 2834485, 19276390.
193. Spugnini EP, Baldi A, Buglioni S, Carocci F, De Bazzichini GM, Betti G, Pantaleo I, Menicagli F, Citro G, Fais S. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2011, 9:221. 10.1186/1479-5876-9-221, 3264547, 22204495.
194. Robey IF, Martin NK. Bicarbonate and dichloroacetate: evaluating pH altering therapies in a mouse model for metastatic breast cancer. BMC Cancer 2011, 11:235. 10.1186/1471-2407-11-235, 3125283, 21663677.
195. Sparks R, Pool T, Smith N, Cameron I. Effects of amiloride on tumor growth and intracellular element content of tumor cells in vivo. Ca Res 1983, 43:73-77.
196. Cragoe EJ, Kleyman TR, Simchowitz L. Amiloride and its Analogs: Unique Cation Transport Inhibitors 1992, New York: Wiley-VCH Publishers.
197. Lorrain J, Briand V, Favennec E, Duval N, Grosset A, Janiak P, Hoornaert C, Cremer G, Latham C, O'Connor SE. Pharmacological profile of SL 59.1227, a novel inhibitor of the sodium/hydrogen exchanger. British J Pharmacol 2000, 131:1188-1194.
198. Atwal KS, O'Neil SV, Ahmad S, Doweyko L, Kirby M, Dorso CR, Chandrasena G, Chen BC, Zhao R, Zahler R. Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors. Bioorg Med Chem Lett 2006, 16:4796-4799. 10.1016/j.bmcl.2006.06.077, 16870436.
199. Harguindey S. The pH in the Etiopathogenesis and Treatment of Cancer 1990, Bilbao, Spain: Department of Embriology, The University of the Basque Country (EHU), Ph D Thesis.
200. Gatenby RA. A change of strategy in the war on cancer. Nature 2009, 459:508-509. 10.1038/459508a, 19478766.